NRx Pharmaceuticals, Inc. (NRXP) Gets FDA Letter Seeking Minor Label Changes for Ketamine

NRx Pharmaceuticals received an FDA Discipline Review Letter requesting minor changes to labeling for its preservative-free ketamine and submission of sample labeling with the proposed proprietary name ahead of the Nov. 10, 2026 ANDA GDUFA goal date.Material DetailsContext by AI AnalystThis is a la…